Carducci, M A <br/><br/>
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Oct 2001 
 - 3047-55 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antineoplastic Agents--adverse effects<br/>Chromatography, High Pressure Liquid<br/>Disorders of Excessive Somnolence--chemically induced<br/>Dose-Response Relationship, Drug<br/>Fatigue--chemically induced<br/>Female<br/>Glutamine--analogs & derivatives<br/>Humans<br/>Hypokalemia--chemically induced<br/>Infusions, Intravenous<br/>Male<br/>Metabolic Clearance Rate<br/>Nausea--chemically induced<br/>Neoplasms--drug therapy<br/>Neutropenia--chemically induced<br/>Patient Dropouts<br/>Phenylacetates--blood<br/>Phenylbutyrates--adverse effects<br/>Prostate-Specific Antigen--blood<br/>Prostatic Neoplasms--blood<br/>Time Factors<br/>Tumor Cells, Cultured<br/>Uric Acid--blood